檢索結果 - Mocci, Simonetta

C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients 由 Patil, Namrata S., Zou, Wei, Mocci, Simonetta, Sandler, Alan, Ballinger, Marcus, Flynn, Susan, Kowanetz, Marcin, Hegde, Priti S.

獲取全文 獲取全文 獲取全文

Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatm... 由 Noé, Johannes, Bordogna, Walter, Archer, Venice, Smoljanovic, Vlatka, Hilton, Magalie, Woodhouse, Ryan, Mocci, Simonetta, Gadgeel, Shirish M.

獲取全文 獲取全文 獲取全文

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab 由 Vennapusa, Bharathi, Baker, Brian, Kowanetz, Marcin, Boone, Jennifer, Menzl, Ina, Bruey, Jean-Marie, Fine, Gregg, Mariathasan, Sanjeev, McCaffery, Ian, Mocci, Simonetta, Rost, Sandra, Smith, Dustin, Dennis, Eslie, Tang, Szu-Yu, Damadzadeh, Bita, Walker, Espen, Hegde, Priti S., Williams, J. Andrew, Koeppen, Hartmut, Boyd, Zachary

獲取全文 獲取全文 獲取全文

Laminin-411 Is a Vascular Ligand for MCAM and Facilitates TH17 Cell Entry into the CNS 由 Flanagan, Ken, Fitzgerald, Kent, Baker, Jeanne, Regnstrom, Karin, Gardai, Shyra, Bard, Frederique, Mocci, Simonetta, Seto, Pui, You, Monica, Larochelle, Catherine, Prat, Alexandre, Chow, Samuel, Li, Lauri, Vandevert, Chris, Zago, Wagner, Lorenzana, Carlos, Nishioka, Christopher, Hoffman, Jennifer, Botelho, Raquel, Willits, Christopher, Tanaka, Kevin, Johnston, Jennifer, Yednock, Ted

獲取全文 獲取全文 獲取全文

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1) 由 Kowanetz, Marcin, Zou, Wei, Gettinger, Scott N., Koeppen, Hartmut, Kockx, Mark, Schmid, Peter, Kadel, Edward E., Wistuba, Ignacio, Chaft, Jamie, Rizvi, Naiyer A., Spigel, David R., Spira, Alexander, Hirsch, Fred R., Cohen, Victor, Smith, Dustin, Boyd, Zach, Miley, Natasha, Flynn, Susan, Leveque, Vincent, Shames, David S., Ballinger, Marcus, Mocci, Simonetta, Shankar, Geetha, Funke, Roel, Hampton, Garret, Sandler, Alan, Amler, Lukas, Mellman, Ira, Chen, Daniel S., Hegde, Priti S.

獲取全文 獲取全文 獲取全文

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH) 由 Peters, Solange, Gettinger, Scott, Johnson, Melissa L., Jänne, Pasi A., Garassino, Marina C., Christoph, Daniel, Toh, Chee Keong, Rizvi, Naiyer A., Chaft, Jamie E., Carcereny Costa, Enric, Patel, Jyoti D., Chow, Laura Q.M., Koczywas, Marianna, Ho, Cheryl, Früh, Martin, van den Heuvel, Michel, Rothenstein, Jeffrey, Reck, Martin, Paz-Ares, Luis, Shepherd, Frances A., Kurata, Takayasu, Li, Zhengrong, Qiu, Jiaheng, Kowanetz, Marcin, Mocci, Simonetta, Shankar, Geetha, Sandler, Alan, Felip, Enriqueta

獲取全文 獲取全文 獲取全文